Delivery Order SPE2DB20D1004-SPE2DB24FF5N8

Award Date 3/6/24
Potential Completion Date 3/7/24
Potential Value $1.4K
Ultimate Awardee
Cencora, Inc.
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,074.90, is for the delivery of Pioglitazone HCL 45 mg tablets. The contract is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC, valued at up to $999,999,999.00, serves as the...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,669.15, is a Firm Fixed Price Delivery Order for the supply of Pioglitazone HCL 45 MG Tablets. The contract has an ultimate completion date of February 7, 2025. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999, which...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,899.44 firm-fixed-price delivery order is for the supply of 500 tablets of 30 mg Pioglitazone HCl, a medication used to treat type 2 diabetes. The contract has an ultimate completion date of November 12, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $1,810.23, is a firm fixed-price delivery order for the supply of pioglitazone HCL 30 mg tablets. The award has no set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award is to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor, for the provision of 4565110842 Pioglitazone HCL 30 MG Tablet 500s. The $1,939.96 fixed-price delivery order was issued by the Defense Logistics Agency (DLA), a defense agency, and has a completion date of July 11, 2024. This award is not designated as a set-aside contract. Amerisourcebergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award, valued at $1,222.01, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, which is a Delivery Order under a broader Indefinite Delivery Contract (IDC) with the DLA, is for the supply of 4566832860 Pioglitazone HCL 30 mg tablets. The IDC, valued at $999,999,999, serves as a primary vehicle for AmerisourceBergen to provide a comprehensive range of...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,698.25 firm fixed-price delivery order is for the supply of Pioglitazone HCL 45 mg tablets, a medication used to treat type 2 diabetes. This contract is not designated as a set-aside requirement. The award is associated with a larger Indefinite Delivery Contract (IDC) worth $999,999,999 that AmerisourceBergen...
This federal contract award, valued at $1,191.52, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, which is a delivery order under an Indefinite Delivery Contract (IDC) with the DLA, covers the provision of Pioglitazone HCL 15 mg tablets. The IDC, valued at $999,999,999, serves as a primary vehicle for Amerisourcebergen to supply a comprehensive range of...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $3,375.08, is for the delivery of pioglitazone HCL 30 mg tablets, a medication used to treat type 2 diabetes. The contract is a Firm Fixed Price Delivery Order with a period of performance through December 20, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, with a ceiling value of $2,170.32, is for the delivery of 500 tablets of Pioglitazone HCL 30 mg, a medication used to treat type 2 diabetes. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen's parent company, Cencora,...
  • SPE2DB20D1004
    Indefinite Delivery Contract
  • SPE2DB20D1004-SPE2DB24FF5N8
    Delivery Order

This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,374.09, is for the delivery of 4,563,880 units of the prescription medication Pioglitazone HCL 45 mg Tablet.

The award is a delivery order under Amerisourcebergen's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

In addition to the DLA contract, Amerisourcebergen also holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs. These IDCs demonstrate Amerisourcebergen's capacity to meet the diverse and critical pharmaceutical needs of multiple government agencies on a large scale.

Generated 5/14/25, 10:32 AM